• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

DNDi statement on KaloBios’ intention to raise price of Chagas drug and file for FDA priority review

New York, USA — 14 Dec 2015
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

As reported this weekend in the New York Times, the pharmaceutical company KaloBios has announced its intention to register the drug benznidazole with the United States Food and Drug Administration (FDA) and to charge exorbitant prices for this treatment, which is an essential medicine for Chagas disease, the leading parasitic killer in Latin America. By registering this drug in the U.S., KaloBios also hopes to obtain a neglected disease “priority review voucher,” which it would likely be able to sell for a large sum – the latest “priority review voucher” was sold for $350 million.

Although details about this move are still emerging, documents filed with the US Securities and Exchange Commission (SEC) show that KaloBios intends to price benznidazole at levels “similar to Hepatitis C antivirals,” which are some of the most highly-priced drugs on the planet. Currently, benznidazole is available in many Latin American countries for $60-100, while the new generation of Hepatitis C antivirals cost up to $94,000.

“At this point, we see the move by KaloBios as a direct threat to access to affordable benznidazole both in the U.S. and Latin America,” said Dr Bernard Pécoul, Executive Director of the Drugs for Neglected Diseases initiative (DNDi). “Sustainable access to Chagas treatment is an urgent public health priority that will be deeply compromised if benznidazole is priced out reach for those who need it most.”

An estimated 5.7 million people are infected with Chagas disease, which is transmitted by the bite of the triatomine, also known as the ‘kissing bug’, a blood-sucking insect found in the Americas. It can also be transmitted from mother to child or through blood transfusions, organ transplantation, and less frequently through foodborne exposure. Despite this burden, less than 1% of those in need currently receive treatment.

Benznidazole is one of only two drugs used to treat Chagas – the other is called nifurtimox and has serious side effects. Despite the need for improved treatments, benznidazole is currently a vital tool in the practically empty therapeutic toolbox to combat Chagas disease. The drug was developed in the 1970s (see timeline below) and is now on the Essential Medicines List of the World Health Organization (WHO).

Although the overwhelming majority of Chagas disease patients live in Latin America, DNDi and many others have long pushed for U.S. FDA approval of benznidazole to ensure broader access to treatment for the estimated 300,000 Chagas disease patients in the U.S. Unfortunately, the latest announcement about pricing by controversial biotech entrepreneur Martin Shkreli, who became the CEO of KaloBios after recently acquiring the company, does not bode well for these patients. The socio-demographics of Chagas patients in the US are poorly known. However, information suggests that many of them are likely to have little access to health services. Currently, benznidazole is available for free from the US Centers for Disease Control and Prevention (CDC) through a clinical trial protocol, but providers need to go through a lengthy and bureaucratic application process.

DNDi and others are equally troubled by KaloBios’ intention to apply for a FDA Priority Review Voucher (PRV) for benznidazole, a decades-old drug. Chagas was recently added to the list of eligible diseases for this program, which awards a voucher to companies that receive FDA approval for a drug to treat one of a list of neglected diseases. Vouchers can be used to fast track a drug application of the company’s choice or resold.

KaloBios has not conducted significant research and development (R&D) for benznidazole, nor does it intend to do so as per the company’s statements. The company appears to have the sole intention of registering benznidazole in the U.S. to obtain the lucrative PRV, without taking the necessary steps to ensure its affordability.

“The FDA PRV program has the potential to be a powerful incentive for companies to conduct research and development for neglected diseases, but unfortunately there are serious loopholes that allow companies to get vouchers when they have barely invested into R&D, and to profit while not committing to make their products accessible to patients in need,” said Rachel Cohen, Regional Executive Director of DNDi North America. “We could face a nightmare situation for Chagas patients and health care providers in the US: the drug will finally be registered, but it could be even less accessible than it is today.”

DNDi, Médecins Sans Frontières/Doctors Without Borders (MSF), and other public health organizations recently detailed concerns about the PRV in an open letter to the U.S. Senate. One of the main demands was that the PRV program should require an access strategy to ensure patients, governments and health care providers have affordable and appropriate access to products for which a PRV has been awarded.

“As we work to dramatically scale up access to diagnosis and treatment of Chagas disease with currently available treatments, R&D needs to be stepped up to develop new generation medicines and vaccines for Chagas that are safe, effective, affordable and accessible,” added Dr Pécoul.

Chagas disease is one of DNDi’s priority diseases and the organization is actively engaged in developing new treatments and screening new compounds. DNDi and partners delivered the first pediatric dosage form of benznidazole and is running clinical trials evaluating new regimens or combinations of the drug. Importantly, DNDi is deeply involved in early stage research for entirely new drugs for Chagas disease, including the Neglected Tropical Disease ‘Drug Discovery Booster’, which allows DNDi to simultaneously screen the compound libraries of four pharmaceutical companies.

Short Timeline of Benznidazole

1970s: Roche develops Benznidazole and registers it in several Latin American countries

2003: Roche decides to donate all commercial rights and technology to manufacture benznidazole to the Brazilian government, which produces a generic version of Roche’s product.

2006: Brazilian state laboratory LAFEPE gets marketing authorization for benznidazole

2008: DNDi and LAFEPE enter into a joint development program to develop a pediatric dosage form of benznidazole.

2011: DNDi and LAFEPE’s pediatric formulation, adopted for babies and children, is registered in Brazil.

2012: A consortium in Argentina develops 100 and 50mg dosages of benznidazole are produced and registered in several countries by the Argentinian company, Elea

2013: Pediatric benznidazole is included on WHO essential medicines list for children

2013: DNDi concludes the then first and only randomized placebo-controlled study using benznidazole in adults with Chagas disease, which provides key data and evidence about the efficacy of benznidazole.

2015: Results are published from another randomized-controlled study on the use of benznidazole for patients with chronic Chagas cardiomyopathy, a potentially fatal disease of the heart muscle caused by Chagas parasites. The study shows that benznidazole is effective in clearing the parasite from patients, but has no effect on slowing long-term heart disease. This confirms the need for early treatment of Chagas patients.

#

Media Contacts:
Ilan Moss
imoss@dndi.org
+1 646 266 5216

Violaine Dällenbach
vdallenbach@dndi.org
+41 22 906 92 47

Chagas disease

Read, watch, share

Loading...
Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

Lab activities
News
20 Feb 2023

First in-person Dengue Alliance meeting brings together experts from dengue-endemic countries to develop treatments for a growing viral threat

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo